CVE-2017-17678
published 2021-05-19CVE-2017-17678: BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.
PriorityP423medium6.1CVSS 3.1
AVNACLPRNUIRSCCLILAN
EPSS
0.84%
53.4th percentile
BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.
Affected
1 ranges
| Vendor | Product | Version range | Fixed in |
|---|---|---|---|
| bmc | remedy_mid-tier | — | — |
CVSS provenance
nvdv3.16.1MEDIUMCVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N
nvdv2.04.3MEDIUMAV:N/AC:M/Au:N/C:N/I:P/A:N
Stop checking back — get the weekly exploitation signal.
Every Monday: what got weaponized or added to CISA KEV in the last seven days — each CVE cross-linked to its PoC, Nuclei template, and detection rule. Free, one email a week, unsubscribe in one click.
No detection rules found.
No public exploits indexed.
No writeups or analysis indexed.
http://bmc.comhttp://remedy.comhttps://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.htmlhttps://seclists.org/fulldisclosure/2017/Oct/52http://bmc.comhttp://remedy.comhttps://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.htmlhttps://seclists.org/fulldisclosure/2017/Oct/52
2021-05-19
Published